|
Report Date : |
25.03.2014 |
IDENTIFICATION DETAILS
|
Name : |
DAMLORAN RAZAK
PHARMACEUTICAL COMPANY |
|
|
|
|
Registered Office : |
No 4, Pravin St
West Dr. Fatemi Ave, Tehran, |
|
|
|
|
Country : |
Iran |
|
|
|
|
Date of Incorporation : |
16.08.2004 |
|
|
|
|
Com. Reg. No.: |
733 |
|
|
|
|
Legal Form : |
Private Joint
Stock |
|
|
|
|
Line of Business : |
Manufacture of a wide range of veterinary medicines in several
therapeutic groups including Anthelmintic, Antibiotics, Anti bloat,
Appetizers, Disinfectants, Growth promoters, Mucolytic, Probiotics and
Vitamins marketed in various pharmaceutical forms comprising Water
soluble powder and granule, oral solution, suspension, bolus, tablet, topical
solution |
|
|
|
|
No. of Employees : |
120 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2013
|
Country Name |
Previous Rating (30.06.2013) |
Current Rating (30.09.2013) |
|
Iran |
B1 |
B1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
IRAN - ECONOMIC OVERVIEW
Iran's economy is marked by statist policies, an inefficient state sector, and reliance on oil, a major source of government revenues. Price controls, subsidies, and other distortions weigh down the economy, undermining the potential for private-sector-led growth. Private sector activity is typically limited to small-scale workshops, farming, some manufacturing, and services. Significant informal market activity flourishes and corruption is widespread. New fiscal and monetary constraints on Tehran, following the expansion of international sanctions in 2012 against Iran's Central Bank and oil exports, significantly reduced Iran's oil revenue, forced government spending cuts, and fueled a 60% currency depreciation. Economic growth turned negative in 2012 and 2013, for the first time in two decades. Iran continues to suffer from double-digit unemployment and underemployment. Lack of job opportunities has convinced many educated Iranian youth to seek jobs overseas, resulting in a significant "brain drain." However, the election of President Hasan RUHANI in June 2013 brought about widespread expectations of economic improvements and greater international engagement among the Iranian public, and early in Ruhani's term the country saw a strengthened national currency and a historic boost to market values at the Tehran Stock Exchange
|
Source
: CIA |
Company Name:
DAMLORAN RAZAK PHARMACEUTICAL COMPANY
Also Trade
as: -
Address: No 4, Pravin St West Dr. Fatemi Ave, Tehran, Iran
Tel: + 98 21 66945732
Fax: + 98 21 66945736
Website: www.damloran.com
E-mail:
info@damloran.com
Company was originally started as an
on 2004
Current Legal Form: Private Joint Stock
Registration Address: No 4, Pravin St West Dr. Fatemi Ave, Tehran, Iran
Registration Number: 733
Registration Date: 16/08/2004
Registration Town: Tehran
National id:
10740034217
Capital:
0,800,000,000 Iranian Rials
Shareholders:
|
Shareholder Name |
Share % |
|
Mr. Ezatollah Mohammadpour |
40% |
|
Mr. Ahmad Karbasi |
40% |
|
Mr. Majid Norouzi |
10% |
|
Mr. Hamidreza
Shaddel Basir |
10% |
Name: Mr. Ezatollah
Mohammadpour
Position within the company: Managing Director, Vice Chairman
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi-English
Name: Mr. Ahmad Karbasi
Position within the company: Chairman
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi- English
Name:
Mr. Majid Norouzi
Position within the company: Member
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi, English
Name: Mr. Hamidreza Shaddel Basir
Position within the company: Member, Director
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi, English
Manufacture of a wide range of veterinary medicines in
several therapeutic groups including Anthelmintic, Antibiotics, Anti
bloat, Appetizers, Disinfectants, Growth promoters, Mucolytic, Probiotics and
Vitamins marketed in various pharmaceutical forms comprising Water
soluble powder and granule, oral solution, suspension, bolus, tablet, topical
solution And premix. These wide categories of products enable the
specialists to choose a flexible and Effective therapy for most of diseases and
nutritional deficiencies.
Local Reporters consider the investigated company to be Medium in their field of concern
Company Employs: 120
Sales: 100% Nationally
Sales to: Group companies, General Public
Sales Term: Cash, Bank
Transfer, accept credit, Letter of credit
Vehicles: 8
Operates Form:
Owned: Office, Factory
Location: Central
Business Area, Main Road,
Bank Mellat
Iran
Auditor: Pouya Gostar Auditing Company
Solicitor: Delamipour va Hamkaran Auditing Company
Imports From: South Korea, India
Importing Terms: Bank
Transfer
Import % and type of product: 10% Finished Goods
Export % and type of product: Subject does not export
Affiliates:
Daroupaksh Company
Iran
Laboratories Razak Company
Iran
Taamin Pharmaceutical Investment Company
Iran
Saba Tamin Investment Company
Iran
Oxir Pharmaceutical Company
Iran
Subject's payments reported to be: NO COMPLAINTS
Following to the interview with Mr. Hamidreza Shaddel Basir ( Member,
Director), he confirmed it.
Local Reputation:
The company being investigated is considered by local reporters to be a Medium Trade Risk
Local informants consider granting of credit to be a fair trade risk
Owner/Shareholders Comments: Some of the owners / shareholders have an active participation in the running of the business.
Age of Business: Old business
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.60.70 |
|
|
1 |
Rs.100.11 |
|
Euro |
1 |
Rs.83.81 |
INFORMATION DETAILS
|
Report Prepared
by : |
NIS |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to
overcome financial difficulties seems comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major sections
of this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.